Phase I/II Clinical Trial Results Of New Cancer Drug, Beta-Alethine (Beta LT(TM)), Presented At International Society Of Hematology (Toronto)

Market Wire, 20050229

LifeTime Pharmaceuticals ("LifeTime") announced today that results of a Phase I/II clinical trial for Beta-alethine (Beta LT), a new drug designed to stimulate the immune system, will be presented today at the International Society of Hematology (ISH) in Toronto. This is the first international oral presentation on the compound.

Floyd Taub, M.D., LifeTime's Chairman, will be presenting at the Toronto Metro Convention Center at 3:30 PM Central Standard Time (CST).

Dr. Taub's presentation will describe the beta- alethine molecule (beta-alanyl cysteamine disulfide) and its development including pre- clinical data on human cells in culture in vitro and data from over 12 animal models. He will focus on data from the first human trial at McGill University (Jewish General Hospital) in Montreal, Canada indicating that Beta LT(TM) enhances the immune system and can have anti-cancer effects, while showing minimal toxicity, if any.

Acopy of the presentation slides is available online at www.ltpharma.com.

LifeTime recently commenced its first U.S. clinical trials at four U.S. sites: Rockville and Baltimore, Maryland; Atlanta, Georgia; and Boulder, Colorado.

LifeTime(TM) Pharmaceuticals, a privately-funded, clinical stage pharmaceutical company, is dedicated to clinical testing and developing non- toxic small molecules that regulate the bone marrow, monocytes and lymphocytes. LifeTime focuses on the development of drugs that are safe enough for long-term, chronic administration to eliminate and prevent reoccurrence of potentially fatal cancer and infectious syndromes.

For more information, please contact Char Tara Albert at (301) 405-0608. Reporters are requested to contact Nancy Rose at (202) 244-1024 or (202) 262-6996 (mobile).

387 Technology Drive College Park, Maryland 20742 (301) 314-1480 (301) 405-9187 Fax